Working toward a future where late-stage breast cancer is a rarity by developing products to help detect it at its earliest stages.
We are developing comprehensive solutions to complex problems along the entire care continuum with the brightest minds, leading institutions, and a real-time R&D lab.
Our Story
Whiterabbit was founded in 2017 to redefine the breast cancer screening and diagnosis experience, in order to improve patient outcomes.
From the start, we’ve focused on developing innovative software products that address critical issues in the cancer screening process that enhance provider accuracy and outcomes. We believe the right technology will empower patient engagement by improving the quality of care.
“I have spent my career improving the practice of early breast cancer detection. I am proud to continue this work as CEO of Whiterabbit, a pioneer in the application of AI tech for cancer screening.
The Whiterabbit team is our greatest asset we have in pursuit of our lofty ambitions. Because of them, I sincerely believe that we are uniquely positioned to change the way mammography is perceived, delivered, and interpreted, to the benefit of our patients and our clients.”
Alexander Sardiña, MD
CEO, Whiterabbit.ai
Our Journey
Clinic Operations
In the early days of the company, we owned and operated 9 outpatient radiology sites, developing within our DNA a deep appreciation of clinical operations and constraints.
This early operational experience helped us understand the needs and pain points of our direct customers and theirs, the patient. These clinics served as the breeding grounds for R&D starting with ACT, our compliance improvement software which launched in 2018.
Our Journey
Clinic Operations
In the early days of the company, we owned and operated 9 outpatient radiology sites, developing within our DNA a deep appreciation of clinical operations and constraints.
This early operational experience helped us understand the needs and pain points of our direct customers and theirs, the patient.
Research and DevelopmentWe continue to advance our mission with several patents pending and products in development that stem from a proprietary data set across more than 2 million patients and partnerships with industry leading institutions. At the core of it all is our exceptional team of over 50 AI scientists, engineers, and innovative healthcare professionals.
Collaborations with industry-leading institutionsTo make our mission a reality, we needed a premier dataset to drive the efficacy and accuracy of our products. Collaborating with leading academic and professional institutions has been essential since day one. Our collaborators continue to play a pivotal role as we build on our suite of groundbreaking and life-changing products.
Research and DevelopmentWe continue to advance our mission with several patents pending and products in development that stem from a proprietary data set across more than 2 million patients and partnerships with industry leading institutions. At the core of it all is our exceptional team of over 130 AI scientists, engineers, and innovative healthcare professionals.
Partnerships with industry-leading institutionsTo make our mission a reality, we needed a premier dataset to drive the efficacy and accuracy of our products. Partnerships leading academic and professional institutions have been essential since day one. Our partners continue to play a pivotal role as we build on our suite of groundbreaking and life-changing products.
Expanded access to AI
In 2023 we launched a collaboration with the American College of Radiology Data Science Institute - making our AI-driven breast density software WRDensity the first FDA-cleared, commercial algorithm available on ACR's AI-Lab platform.
ACR's AI-LAB is designed to democratize AI by simplifying the evaluation and adoption of AI products and empowering radiologists to develop algorithms at their own institutions to meet their unique clinical needs.
Learn MoreWhat our users say
“Whiterabbit has helped RadNet to better mine our data, allowing us to significantly enhance patient compliance with screening mammography guidelines and to more accurately measure our screening capacity and expansion opportunities. They have been a valued business partner in our efforts to create enhanced awareness of breast cancer screening and in growing our mammography volume.”
Stephen M. Forthuber
President and Chief Operating Officer, Eastern Operations
Find out how our products can help your business improve patient outcomes.
